StockData
Keros Therapeutics, Inc. logo

Keros Therapeutics, Inc. (KROS) stock

KROSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$11.31+1.28 (+12.76%)

Close on Nov 17, 2026Market cap $224.25MP/E –Yield –

Keros Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Keros Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$47.99M, down 187.2% year over year. For fiscal 2025 it was $107.51M. The highest annual figure on record is $107.51M in fiscal 2025.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$107.51M–
FY2024Dec 31, 2024-$160.87M–
FY2023Dec 31, 2023-$124.51M–
FY2022Dec 31, 2022-$70.06M–
FY2021Dec 31, 2021-$62.15M–
FY2020Dec 31, 2020-$36.89M–
FY2019Dec 31, 2019-$16.00M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$20.42M–
Q1 FY2026Mar 31, 2026-$3.53M-102.2%
Q4 FY2025Dec 31, 2025-$27.29M–
Q3 FY2025Sep 30, 2025$3.25M–
Q2 FY2025Jun 30, 2025-$29.62M–
Q1 FY2025Mar 31, 2025$161.17M–
Q4 FY2024Dec 31, 2024-$46.01M–
Q3 FY2024Sep 30, 2024-$30.50M–
Q2 FY2024Jun 30, 2024-$39.80M–
Q1 FY2024Mar 31, 2024-$44.56M–
Q4 FY2023Dec 31, 2023-$25.46M–
Q3 FY2023Sep 30, 2023-$33.98M–
Q2 FY2023Jun 30, 2023-$30.83M–
Q1 FY2023Mar 31, 2023-$34.24M–
Q4 FY2022Dec 31, 2022-$21.44M–
Q3 FY2022Sep 30, 2022-$24.60M–
Q2 FY2022Jun 30, 2022-$22.59M–
Q1 FY2022Mar 31, 2022-$1.43M–
Q4 FY2021Dec 31, 2021-$19.57M–
Q3 FY2021Sep 30, 2021-$14.44M–
Q2 FY2021Jun 30, 2021-$17.64M–
Q1 FY2021Mar 31, 2021-$10.51M–
Q4 FY2020Dec 31, 2020-$7.99M–
Q3 FY2020Sep 30, 2020-$10.86M–
Q2 FY2020Jun 30, 2020-$9.93M–
Q1 FY2020Mar 31, 2020-$8.12M–
Q4 FY2019Dec 31, 2019-$5.50M–
Q3 FY2019Sep 30, 2019-$2.96M–
Q2 FY2019Jun 30, 2019-$5.03M–
Q1 FY2019Mar 31, 2019-$2.51M–

More Keros Therapeutics figures

See a number that looks wrong?